Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Total Liabilities (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Total Liabilities over the past 3 years, most recently at $32.0 million for Q4 2025.

  • Quarterly results put Total Liabilities at $32.0 million for Q4 2025, up 37.24% from a year ago — trailing twelve months through Dec 2025 was $32.0 million (up 37.24% YoY), and the annual figure for FY2025 was $32.0 million, up 37.24%.
  • Total Liabilities for Q4 2025 was $32.0 million at Tonix Pharmaceuticals Holding, up from $21.3 million in the prior quarter.
  • Over the last five years, Total Liabilities for TNXP hit a ceiling of $48.9 million in Q4 2023 and a floor of $12.5 million in Q1 2025.
  • Median Total Liabilities over the past 3 years was $21.0 million (2024), compared with a mean of $23.7 million.
  • Biggest five-year swings in Total Liabilities: soared 99.11% in 2024 and later tumbled 54.14% in 2025.
  • Tonix Pharmaceuticals Holding's Total Liabilities stood at $48.9 million in 2023, then tumbled by 52.32% to $23.3 million in 2024, then skyrocketed by 37.24% to $32.0 million in 2025.
  • The last three reported values for Total Liabilities were $32.0 million (Q4 2025), $21.3 million (Q3 2025), and $19.4 million (Q2 2025) per Business Quant data.